Related Experiment Video
Updated: Aug 7, 2026
09:21
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Argatroban: update
1Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
American Heart Journal
|June 20, 2006
Summary
Argatroban, a direct thrombin inhibitor, shows promise as an effective anticoagulant. It is comparable to heparin in certain conditions and beneficial for patients with heparin-induced thrombocytopenia.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Hematology
Background:
- Unfractionated heparin is a traditional anticoagulant for thrombotic diseases.
- Limitations of heparin led to the development of direct thrombin inhibitors.
- Argatroban is a synthetic small molecule inhibitor of thrombin.
Purpose of the Study:
- To evaluate argatroban's efficacy and safety compared to heparin.
- To explore argatroban's role in various thrombotic conditions.
- To assess argatroban's utility in specific patient populations.
Main Methods:
- Preclinical studies in animal models of arterial thrombosis.
- Clinical trials in ST-elevation myocardial infarction and percutaneous coronary interventions.
- Observational studies in patients with heparin-induced thrombocytopenia.
Main Results:
- Argatroban demonstrated superior efficacy over heparin in preclinical arterial thrombosis models.
- Argatroban showed comparable efficacy to heparin in ST-elevation myocardial infarction management.
- Argatroban significantly reduced thrombotic events in patients with heparin-induced thrombocytopenia.
Conclusions:
- Argatroban is an effective alternative anticoagulant, particularly in heparin-induced thrombocytopenia.
- Argatroban shows potential in percutaneous coronary interventions and myocardial infarction.
- Further research is needed to confirm argatroban's efficacy across diverse clinical scenarios.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:19Depolarizing Blockers: Pharmocokinetics
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...